Skyepharma continues to make excellent progress in multiple areas of the business. The recent recognition of a €10m flutiform® sales milestone highlights the continued strong sales growth of the product whilst work continues in parallel to add additional indications and geographies. The development products SKP-2075 and SKP-2076 could also potentially add significant value to the group’s respiratory franchise. We continue to believe that Skyepharma has further strong growth potential.